ClinicaliQ Trial Snapshot
- Identifying Immune Biomarkers of Disease and Disease Control in Autoimmune Neurological Disease Using Autologous Haematopoietic Stem Cell Transplantation — Recruiting • Oncology • NCT06195800.
- What is being tested: Identification of immune biomarkers that predict disease activity and treatment response in autoimmune neurological diseases (particularly MS) using autologous haematopoietic stem cell transplantation (aHSCT) as a model to understand disease mechanisms.
- Patient eligibility overview: The trial enrolls patients with immune-mediated neurological diseases, primarily Multiple Sclerosis, who are candidates for aHSCT as a treatment intervention.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The underlying disease mechanisms which occur in patients with immune mediation neurological diseases, such as Multiple Sclerosis (MS), are incompletely understood. For such patients, autologous haematopoietic stem cell transplantation (aHSCT) has been increasingly used as a highly successful one-off treatment for some patients. This treatment aims to delete the faulty immune system with a course of chemotherapy and then 'reboot' the immune system using a patients' own stem cells (a cell with the unique ability of being a building block to create many different cells in the body) to stop…
Eligibility Snapshot
- : 1. Diagnosis of a immune mediated neurological disease according to disease specific criteria (active treatment arm) or diagnosis of relapsing remitting multiple sclerosis (control arm). 2. Treatment with autologous haematopoetic stem cell transplantation (active treatment arm) or high efficacy disease modifying treatment (control arm). 3. Willing to provide biological samples for analysis and undergo clinical assessments for the duration of follow up. 4. Able to understand English and provide informed consent.
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.